Treatment Outcomes and Associated Factors of Intravenous Colistin for Nosocomial Infections in Pediatric Patients: A Retrospective Study in a University Hospital in Thailand

被引:1
作者
Khamlek, Sunisa [1 ,2 ]
Lucksiri, Aroonrut [3 ]
Sunkonkit, Kanokkarn [4 ]
Oberdorfer, Peninnah [5 ]
Sukwuttichai, Pattarapan [3 ,6 ]
机构
[1] Chiang Mai Univ, Fac Pharm, PhDs Degree Program Pharm, Chiang Mai, Thailand
[2] Univ Phayao, Sch Pharmaceut Sci, Dept Pharmaceut Care, Div Clin Pharm, Phayao, Thailand
[3] Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Care, 239 Suthep Rd, Chiang Mai 50200, Thailand
[4] Chiang Mai Univ, Fac Med, Dept Pediat, Div Pulm & Crit Care, Chiang Mai, Thailand
[5] Chiang Mai Univ, Fac Med, Dept Pediat, Div Infect Dis, Chiang Mai, Thailand
[6] Chiang Mai Univ, Fac Pharm, Pharmaceut Care Training Ctr, Dept Pharmaceut Care, Chiang Mai, Thailand
关键词
colistin; efficacy; safety; child; nosocomial infection; CRITICALLY-ILL CHILDREN; COMBINATION; EFFICACY; CRITERIA; RISK;
D O I
10.1097/INF.0000000000004450
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: This study aimed to investigate the efficacy and safety of intravenous colistin in pediatric patients with nosocomial Gram-negative bacteria infections and to determine factors associated with treatment outcomes. Methods: This retrospective study recruited patients <18 years of age receiving intravenous colistin between January 2014 and December 2018. Clinical data and treatment outcomes were reviewed, and factors associated with treatment outcomes were assessed. Results: This study included 178 patients with a median age of 3.4 years (range, 0.1-17.8). The mean +/- SD dose of colistin prescribed to patients without renal impairment was 5.1 +/- 0.6 mg/kg/day. The clinical response rate was 70.8% in patients receiving colistin for specific treatment. Infection-related mortality and crude mortality were 17.5% and 19.7%, respectively. The nephrotoxicity rate was 29.8%; approximately 70% of the episodes occurred between the 3rd and 7th day of treatment. The presence of at least 2 organ dysfunctions [adjusted hazard ratio (aHR): 7.17; 95% CI: 1.64-31.40], septic shock (aHR: 2.69; 95% CI: 1.36-5.32) and receiving chemotherapy/immunosuppressants (aHR: 2.68; 95% CI: 1.36-5.25) were observed to be associated with clinical failure. The factors observed to be associated with nephrotoxicity included hypoalbuminemia (aHR: 2.93; 95% CI: 1.26-6.78), receiving amphotericin B (aHR: 2.29; 95% CI: 1.16-4.52), vancomycin (aHR: 3.36; 95% CI: 1.50-7.56) and vasopressors (aHR: 2.57; 95% CI: 1.27-5.21). Conclusion: Colistin is generally effective in the treatment of nosocomial Gram-negative bacteria infections in pediatric patients. Close monitoring of renal function should be considered, especially in high-risk patients. Optimal dosage regimens for pediatric populations to promote more favorable clinical outcomes and minimize nephrotoxicity require further investigation.
引用
收藏
页码:1054 / 1060
页数:7
相关论文
共 39 条
[31]   Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health System [J].
Pogue, Jason M. ;
Lee, Jiha ;
Marchaim, Dror ;
Yee, Victoria ;
Zhao, Jing J. ;
Chopra, Teena ;
Lephart, Paul ;
Kaye, Keith S. .
CLINICAL INFECTIOUS DISEASES, 2011, 53 (09) :879-884
[32]   Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children [J].
Polat, Meltem ;
Kara, Soner Sertan ;
Tapisiz, Anil ;
Tezer, Hasan ;
Kalkan, Gokhan ;
Dolgun, Anil .
PEDIATRIC DRUGS, 2015, 17 (04) :323-330
[33]   Risk factors for colistin-associated nephrotoxicity [J].
Rattanaumpawan, Pinyo ;
Ungprasert, Puangpaka ;
Thamlikitkul, Visanu .
JOURNAL OF INFECTION, 2011, 62 (02) :187-190
[34]   Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity? [J].
Saelim, Weerayuth ;
Changpradub, Dhitiwat ;
Thunyaharn, Sudaluck ;
Juntanawiwat, Piraporn ;
Nulsopapon, Parnrada ;
Santimaleeworagun, Wichai .
INFECTION AND CHEMOTHERAPY, 2021, 53 (01) :128-140
[35]  
SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
[36]  
Thailand Food and Drug Administration, 2014, Colistin-150 injectionpackage insert
[37]   Antibiotic Dosing in Multiple Organ Dysfunction Syndrome [J].
Ulldemolins, Marta ;
Roberts, Jason A. ;
Lipman, Jeffrey ;
Rello, Jordi .
CHEST, 2011, 139 (05) :1210-1220
[38]   Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study [J].
Wacharachaisurapol, Noppadol ;
Sukkummee, Warumphon ;
Anunsittichai, Orawan ;
Srisan, Panida ;
Sangkhamal, Siriporn ;
Chantharit, Prawat ;
Vandepitte, Warunee Punpanich ;
Wattanavijitkul, Thitima ;
Puthanakit, Thanyawee .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 109 :230-237
[39]   Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients [J].
Wacharachaisurapol, Noppadol ;
Phasomsap, Chayapa ;
Sukkummee, Warumphon ;
Phaisal, Weeraya ;
Chanakul, Ankanee ;
Wittayalertpanya, Supeecha ;
Chariyavilaskul, Pajaree ;
Puthanakit, Thanyawee .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (06)